




# PHARMACEUTICAL 2022

BeiGene Ltd.  
Rank 188 of 466





RealRate

# PHARMACEUTICAL 2022

BeiGene Ltd.  
Rank 188 of 466



The relative strengths and weaknesses of BeiGene Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BeiGene Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 36% points. The greatest weakness of BeiGene Ltd. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 169%, being 91% points above the market average of 78%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 7,613,880         |
| Cost of Goods Sold                          | 164,906           |
| Intangible Assets                           | 46,679            |
| Liabilities, Current                        | 1,599,555         |
| Liabilities, Non-Current                    | 803,407           |
| Other Assets                                | 397,785           |
| Other Compr. Net Income                     | 11,008            |
| Other Expenses                              | -24,484           |
| Other Liabilities                           | 0                 |
| Other Net Income                            | 147               |
| Other Revenues                              | 1,176,283         |
| Property and Equipment                      | 587,605           |
| Research and Development                    | 1,459,239         |
| Selling, General and Administrative Expense | 990,123           |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 8,645,949         |
| Liabilities              | 2,402,962         |
| Expenses                 | 2,589,784         |
| Revenues                 | 1,176,283         |
| Stockholders Equity      | 6,242,987         |
| Net Income               | -1,413,354        |
| Comprehensive Net Income | -1,407,850        |
| Economic Capital Ratio   | 169%              |